Insider Trading Alert - ACET, AGCO And ABMD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 28, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $529.45 to $86,394,898.20.

Highlighted Stocks Traded by Insiders:

Aceto (ACET) - FREE Research Report

Alaimo Charles John, who is Senior Vice President at Aceto, sold 2,000 shares at $23.19 on May 28, 2015. Following this transaction, the Senior Vice President owned 14,435 shares meaning that the stake was reduced by 12.17% with the 2,000-share transaction.

The shares most recently traded at $23.13, down $0.06, or 0.26% since the insider transaction. Historical insider transactions for Aceto go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 22,164

The average volume for Aceto has been 119,500 shares per day over the past 30 days. Aceto has a market cap of $700.5 million and is part of the basic materials sector and chemicals industry. Shares are up 8.34% year-to-date as of the close of trading on Thursday.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The stock currently has a dividend yield of 1%. The company has a P/E ratio of 27.3. Currently, there are no analysts who rate Aceto a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACET - FREE

TheStreet Quant Ratings rates Aceto as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Aceto Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AGCO (AGCO) - FREE Research Report

Crain Robert B, who is Sr VP, Gen. Mgr. Americas at AGCO, sold 1,500 shares at $51.71 on May 28, 2015. Following this transaction, the Sr VP, Gen. Mgr. Americas owned 51,973 shares meaning that the stake was reduced by 2.81% with the 1,500-share transaction.

The shares most recently traded at $51.00, down $0.71, or 1.39% since the insider transaction. Historical insider transactions for AGCO go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for AGCO has been 1.1 million shares per day over the past 30 days. AGCO has a market cap of $4.6 billion and is part of the industrial goods sector and industrial industry. Shares are up 14.09% year-to-date as of the close of trading on Thursday.

AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The stock currently has a dividend yield of 0.93%. The company has a P/E ratio of 14.1. Currently, there is 1 analyst who rates AGCO a buy, 4 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGCO - FREE

TheStreet Quant Ratings rates AGCO as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full AGCO Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abiomed (ABMD) - FREE Research Report

Bolt William J, who is SVP, QA and Regulatory Affairs at Abiomed, sold 3,647 shares at $60.41 on May 28, 2015. Following this transaction, the SVP, QA and Regulatory Affairs owned 98,325 shares meaning that the stake was reduced by 3.58% with the 3,647-share transaction.

Greenfield Andrew J, who is VP Healthcare Solutions at Abiomed, sold 3,357 shares at $60.31 on May 28, 2015. Following this transaction, the VP Healthcare Solutions owned 57,227 shares meaning that the stake was reduced by 5.54% with the 3,357-share transaction.

Weber David M, who is Chief Operating Officer at Abiomed, sold 17,968 shares at $60.77 on May 28, 2015. Following this transaction, the Chief Operating Officer owned 117,650 shares meaning that the stake was reduced by 13.25% with the 17,968-share transaction.

Howley Michael G, who is VP, Global Sales & Marketing at Abiomed, sold 4,126 shares at $60.31 on May 28, 2015. Following this transaction, the VP, Global Sales & Marketing owned 73,763 shares meaning that the stake was reduced by 5.3% with the 4,126-share transaction.

The shares most recently traded at $60.11, down $0.20, or 0.33% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares sold: 64,174
  • 12-Week # shares sold: 64,174
  • 24-Week # shares sold: 78,174

The average volume for Abiomed has been 622,000 shares per day over the past 30 days. Abiomed has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 59.14% year-to-date as of the close of trading on Thursday.

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 23.3. Currently, there are 4 analysts who rate Abiomed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings rates Abiomed as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Abiomed Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

To Win at Trade the U.S. Must Act and Behave Like China

To Win at Trade the U.S. Must Act and Behave Like China

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron